✨ Free AI Report
Cencora, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cencora, Inc.
Company Research

Cencora, Inc.: Business Overview, Financials & Competitive Analysis

Cencora, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Cencora's strategic positioning and robust business model underscore its significant role in the pharmaceutical supply chain. Cencora raised its fiscal 2026 adjusted operating income guidance to growth of 11.5 percent to 13.5 percent, demonstrating strong momentum. The company reported 12% growth in adjusted operating income and 9% increase in adjusted.

What is Cencora, Inc.'s industry? Cencora, Inc. (cencora.com) operates in Pharmaceutical Distribution & Healthcare Services. AskCyborg classifies Cencora, Inc. under Pharmaceutical Distribution & Healthcare Services in its company registry.

Cencora is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services. The company reported first-quarter reven...

8/ 10Strong

Cyborg Score thesis

Cencora's strategic positioning and robust business model underscore its significant role in the pharmaceutical supply...

Read the full analyst-debate transcript →
Industry Pharmaceutical Distribution & Healthcare Services
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cencora, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cencora, Inc.

AskCyborg analysts argue the bull and bear cases for Cencora, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cencora, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cencora, Inc. Overview

Pro stress-test →

Cencora is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services. The company reported first-quarter revenue of $85.9 billion for the period ended December 31, 2025, a 5.5 percent increase from the prior year.

Strategic Profile

Pro stress-test →

Cencora is advancing its strategy through acquisitions that cement its position in specialty healthcare. The MSO strategy is a natural extension of Cencora's specialty provider relationships, with acquisitions of Retina Consultants of America and OneOncology providing two platform MSOs with significant capabilities.

Competitive Landscape

Pro stress-test →

Cencora holds commanding market share in the US pharmaceutical wholesale industry alongside McKesson and Cardinal Health. The pharmaceutical wholesale industry is characterized by intense competition and consolidation, which could lead to pricing pressures and margin erosion.

Industry Context

Cencora, Inc. operates in Pharmaceutical Distribution & Healthcare Services.

Key facts

Founded: 1871 · Headquarters: Conshohocken, US · Revenue: $85.9B · Market cap: $69.95B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cencora, Inc..

  • The US Healthcare Solutions segment showed strong performance with 21% increase in operating income, driven by acquisitions and continued specialty growth.
  • The company is leveraging technology and advanced analytics to differentiate its solutions in the market, capitalizing on strong specialty pharmaceutical utilization trends.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Raised fiscal 2026 adjusted operating income guidance to 11.5-13.5% growth from prior 8-10%.
  • February 2026Completed acquisition of majority equity interests in OneOncology, strengthening footprint in oncology-focused management services.
  • +1 moreTrack every material event for Cencora, Inc. as it happens. Explore monitoring →
Get alerted when Cencora, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

McKessonLeading pharmaceutical distributor→Cardinal HealthMajor healthcare services and pharmaceutical distributor→

Compare Cencora, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cencora, Inc. operates in Pharmaceutical Distribution & Healthcare Services. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Distribution & Healthcare Services research →
NEW · MCP server

Ask your AI assistant about Cencora, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cencora, Inc. and its top competitor on Cyborg Score”
“What did Cencora, Inc. do this quarter?”
“Is Cencora, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cencora, Inc. do?+
Cencora is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services. The company reported first-quarter reven...
What is Cencora, Inc.'s Cyborg Score?+
Cencora, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cencora, Inc.'s main competitors?+
Named competitors include McKesson, Cardinal Health. The full competitive landscape is in the AskCyborg report.
How can I get the full Cencora, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cencora, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cencora, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical Distribution & Healthcare Services research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8McKesson Corporation